Fatal outcome of a hypersensitivity reaction to paclitaxel: a critical review of premedication regimens.
D000893:Anti-Inflammatory Agents / Q000008:administration & dosage / Q000627:therapeutic use; D000972:Antineoplastic Agents, Phytogenic / Q000009:adverse effects* / Q000627:therapeutic use; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy; D002974:Clemastine / Q000008:administration & dosage / Q000627:therapeutic use; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D004342:Drug Hypersensitivity / Q000517:prevention & control*; D017809:Fatal Outcome; D006634:Histamine H1 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006635:Histamine H2 Antagonists / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D007262:Infusions, Intravenous; D008175:Lung Neoplasms / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D017239:Paclitaxel / Q000009:adverse effects* / Q000627:therapeutic use; D011899:Ranitidine / Q000008:administration & dosage / Q000627:therapeutic use; D012307:Risk Factors
D000893:Anti-Inflammatory Agents; D000972:Antineoplastic Agents, Phytogenic; D006634:Histamine H1 Antagonists; D006635:Histamine H2 Antagonists; D003907:Dexamethasone; D011899:Ranitidine; D002974:Clemastine; D017239:Paclitaxel